This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Aman U. Buzdar, MD; Sewa S. Legha, MD; Gabriel N. Hortobagyi, MD; George R. Blumenschein, MD
University of Texas System Cancer Center M. D. Anderson Hospital and Tumor Institute Houston

JAMA. 1979;241(18):1893.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

The letter from Israel and Olson (240:1585, 1978) describing congestive heart failure with vinblastine sulfate in a patient previously treated with doxorubicin hydrochloride was of great interest to us. It was mentioned in the letter that recently the patient was treated with mitomycin and vinblastine. It was not clear whether the patient received vinblastine and mitomycin simultaneously or sequentially. It was suggested that vinblastine might have exacerbated doxorubicin-induced myocardial damage. Although vinblastine might have been the causal agent in this instance, the authors should clarify the temporal relationship of congestive heart failure and mitomycin therapy, because mitomycin could have played a role in precipitating this episode. Mitomycin has been reported to be cardiotoxic¹ and has also recently been shown to potentiate the subclinical damage induced by doxorubicin.² . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?